Phase II Study of Doxorubicin and Avastin® in Sarcoma.

Summary

This research is being done to find out if adding a drug called Avastin to an already approved regimen used for soft-tissue sarcoma, Doxorubicin, will improve overall survival, and slow disease progression. The study will also evaluate the overall safety of combining these drugs. It is not known if combining these drugs will improve outcome. Avastin has been approved for the treatment of metastatic carcinoma of the colon or rectum. It is not approved for the treatment of soft-tissue sarcoma when added to Doxorubicin.

Timeline

Start

2008-09

Primary completion

2010-09

Completion

2010-11

Outcome

Outcome not reported

Stopped (Enrollment): “The study has been terminated due to low accrual.”

Drugs

Indications